The positive results from the two-year Romeo study of the OMNI Surgical System indicate that the technology is effective in lowering eye pressure and medication use in cataract surgery. This is likely to increase demand for the product and boost Sight Sciences' stock price in the short term. The absence of serious adverse events also adds to the positive outlook for the company.